Literature DB >> 23543506

Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation.

Serkan Kuyumcu1, Zeynep Gözde Özkan, Yasemin Sanli, Ebru Yilmaz, Ayse Mudun, Isik Adalet, Seher Unal.   

Abstract

PURPOSE: The objective of this study is to determine the range of SUVmax of 68Ga-DOTATATE in normal organs and tumoral lesions and establish uptake unrelated to NET.
MATERIALS AND METHODS: One hundred and twenty patients (57 men, 63 women), who underwent (68)Ga-DOTATATE PET/CT imaging in our institution were analyzed. Patients were indicated for (68)Ga-DOTATATE PET/CT imaging to detect primary tumor or metastasis of suspected or previously known NET, to determine SSTR positivity and to detect occult source of ectopic Cushing syndrome. Normal range of uptake was calculated for the organs that were proven to have no pathology by either conventional radiological imaging or clinical follow-up, using SUVmax as a semiquantitative measure. Uptake and tumor to background (T/B) ratios of tumoral lesions in liver, pancreas, bone, brain and lymph nodes were calculated. Uptakes due to lesions unrelated to NET were also documented.
RESULTS: Significant uptake was found in spleen, kidneys, adrenal glands, liver and pituitary gland with mean SUVmax of 24.67, 14.30, 13.73, 9.12 and 9.74 respectively. Uptake was measured separately for the pancreatic head and body separately, however, besides a slightly heterogeneous uptake; the difference was not statistically significant. Uptake in the tumoral lesions had high (T/B) ratios with mean SUVmax of 28.72, 25.21, 18.28, 34.73 and 12.59 for liver, pancreas, bone, brain and lymph nodes, respectively. Incidental benign tumoral lesions were detected in 3 patients (2.5 %) which were meningioma and fibrous dysplasia demonstrating significant and breast fibroadenoma demonstrating mild (68)Ga-DOTATATE uptake. Non-neoplastic processes were detected in 4 patients (14.1 %), including postsurgical inflammation, reactive lymph nodes, arthritis and demonstrated faint to mild (68)Ga-DOTATATE uptake, with the exception of significant uptake in accessory spleen.
CONCLUSION: (68)Ga-DOTATATE has high T/B ratio with physiological biodistribution comparable to its counterparts. However, the presence of SSTRs in benign and malignant lesions unrelated to NET may be challenging in interpretation particularly where the physiological uptake is variable.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543506     DOI: 10.1007/s12149-013-0718-4

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  16 in total

Review 1.  Functional imaging in ectopic Cushing syndrome.

Authors:  Seda Grigoryan; Anca M Avram; Adina F Turcu
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

2.  Breast Fibroadenoma With Increased Activity on 68Ga DOTATATE PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Samira M Sadowski; Apostolos H Karantanas; Ulas Bagci; Nicholas J Patronas
Journal:  Clin Nucl Med       Date:  2017-02       Impact factor: 7.794

3.  Improving PET Quantification of Small Animal [68Ga]DOTA-Labeled PET/CT Studies by Using a CT-Based Positron Range Correction.

Authors:  Jacobo Cal-Gonzalez; Juan José Vaquero; Joaquín L Herraiz; Mailyn Pérez-Liva; María Luisa Soto-Montenegro; Santiago Peña-Zalbidea; Manuel Desco; José Manuel Udías
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

4.  The Clinical Impact of [68 Ga]-DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone - Secreting Tumours.

Authors:  Taweesak Wannachalee; Adina F Turcu; Irina Bancos; Mouhammed Amir Habra; Anca M Avram; Hubert H Chuang; Steven G Waguespack; Richard J Auchus
Journal:  Clin Endocrinol (Oxf)       Date:  2019-06-12       Impact factor: 3.478

5.  Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.

Authors:  Jillian Maclean; Matthew Aldridge; Jamshed Bomanji; Susan Short; Naomi Fersht
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

Review 6.  The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

Authors:  Amit Tirosh; Electron Kebebew
Journal:  Future Oncol       Date:  2017-10-26       Impact factor: 3.404

7.  Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical center and a literature review.

Authors:  Jianyu Zhu; Lin Lu; Yong Yao; Shi Chen; Wei Li; Hui You; Feng Feng; Ming Feng; Yi Zhang; Zhicheng Wang; Xu Sun; Xiaoxu Li; Huijuan Zhu; Renzhi Wang; Zhaolin Lu
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

8.  The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.

Authors:  Fangling Zhang; Qiao He; Ganhua Luo; Yali Long; Ruocheng Li; Lei Ding; Xiangsong Zhang
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

9.  Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.

Authors:  María Luisa Soto-Montenegro; Santiago Peña-Zalbidea; Jose María Mateos-Pérez; Marta Oteo; Eduardo Romero; Miguel Ángel Morcillo; Manuel Desco
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

10.  An Incidental Solitary Plasmacytoma of Bone Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography.

Authors:  Duygu Has Şimşek; Serkan Kuyumcu; Bilge Bilgiç; Emine Göknur Işık; Cüneyt Türkmen; Işık Adalet
Journal:  Mol Imaging Radionucl Ther       Date:  2016-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.